FOR YOUR PATIENTS
Explaining the Envisia test to patients
The Envisia classifier is a genomic test that aids clinicians in differentiating between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD), without having to do a surgical lung biopsy.
How to explain Envisia to patients
The test analyzes lung tissue samples collected during a transbronchial biopsy (TBB), a nonsurgical procedure commonly used to diagnose lung diseases.
![](https://lung.veracyte.com/wp-content/uploads/2023/08/Envisia_Icon_Tolerability_.png)
A doctor collects 3-5 lung tissue samples during a nonsurgical transbronchial biopsy (TBB) and sends them to the lab.
![](https://lung.veracyte.com/wp-content/uploads/2023/08/Envisia_Icon_Clinical-Factors_Genes.png)
The test looks at 190 genes commonly associated with fibrosis or inflammation.
![](https://lung.veracyte.com/wp-content/uploads/2023/08/Envisia_Icon_Clinical-Factors_Test-Results.png)
The results indicate either positive or negative for usual interstital pneumonia (UIP), which helps guide next steps.
![](https://lung.veracyte.com/wp-content/uploads/2023/12/Envisia_For-Patients_Brochure-YouTube.png)
Patient Resources
This handout and video may help healthcare professionals discuss the Envisia classifier with patients and explain how the test works.
Billing and reimbursement
Client services:
1.844.464.5864
Customer support:
support@veracyte.com
Covered by Medicare
The Envisia test is covered by Medicare. Veracyte bills Medicare and third-party payers directly.
The Veracyte Access Program provides financial support for both eligible uninsured and commercially available insured patients with financial need.